A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Study Summary

This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).

Conditions

Iron Deficiency Anemia

Interventions / Drugs

ferumoxytol Iron sucrose

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment75 participants

Primary Completion—

Lead SponsorAMAG Pharmaceuticals, Inc.

Data Retrieved2026-04-11 02:53:30.727973+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.